October 7, 2025 — Leads & Copy — Oragenics, a clinical-stage biotechnology company, has announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of brain-targeted therapeutics. The partnership aims to leverage AI modeling to identify optimal receptor binding profiles for compounds acquired by Oragenics in 2023, potentially enabling more efficient and targeted laboratory validation.
According to Janet Huffman, Chief Executive Officer of Oragenics, the partnership demonstrates a commitment to innovation. Receptor.AI will apply its computational models to analyze Oragenics’ molecule structures, predicting which receptors are most likely to bind with therapeutic effect. This data will inform Oragenics’ laboratory testing strategy, potentially identifying therapeutic applications across neurological and psychiatric indications like Alzheimer’s, Parkinson’s, PTSD, opioid addiction, and anxiety disorders.
Dr. Alan Nafiiev, Chief Executive Officer of Receptor.AI, stated that this collaboration reflects the practical value of applying AI to early-stage development. Oragenics remains focused on advancing ONP-002 through Phase IIa trials for concussion treatment, expected in Q4 2025, while strategically positioning itself as a leader in intranasal neurological pharmaceuticals.
Oragenics is developing ONP-002 as a potential treatment for concussion and mild traumatic brain injury, advancing it into Phase IIa clinical trials in Australia, with U.S. Phase IIb trials planned to follow.
Contact:
Janet Huffman, Chief Executive Officer of Oragenics.
Source: Oragenics
